135 related articles for article (PubMed ID: 20173085)
1. Effect of raltegravir on the pharmacokinetics of methadone.
Anderson MS; Mabalot Luk JA; Hanley WD; Jin B; Riesenberg RA; Wenning LA; Chodakewitz JA; Wagner JA; Iwamoto M
J Clin Pharmacol; 2010 Dec; 50(12):1461-6. PubMed ID: 20173085
[TBL] [Abstract][Full Text] [Related]
2. Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.
Anderson MS; Kakuda TN; Hanley W; Miller J; Kost JT; Stoltz R; Wenning LA; Stone JA; Hoetelmans RM; Wagner JA; Iwamoto M
Antimicrob Agents Chemother; 2008 Dec; 52(12):4228-32. PubMed ID: 18838586
[TBL] [Abstract][Full Text] [Related]
3. Effect of saquinavir/ritonavir (1000/100 mg bid) on the pharmacokinetics of methadone in opiate-dependent HIV-negative patients on stable methadone maintenance therapy.
Jamois C; Smith P; Morrison R; Riek M; Patel A; Schmitt C; Morcos PN; Zhang X
Addict Biol; 2009 Jul; 14(3):321-7. PubMed ID: 19523046
[TBL] [Abstract][Full Text] [Related]
4. Dolutegravir does not affect methadone pharmacokinetics in opioid-dependent, HIV-seronegative subjects.
Song I; Mark S; Chen S; Savina P; Wajima T; Peppercorn A; Bala U; Geoffroy P; Piscitelli S
Drug Alcohol Depend; 2013 Dec; 133(2):781-4. PubMed ID: 24018316
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects.
Cao YJ; Smith PF; Wire MB; Lou Y; Lancaster CT; Causon RC; Bigelow GE; Martinez E; Fuchs EJ; Radebaugh C; McCabe S; Hendrix CW
Pharmacotherapy; 2008 Jul; 28(7):863-74. PubMed ID: 18576901
[TBL] [Abstract][Full Text] [Related]
6. Raltegravir: the first HIV integrase inhibitor.
Cocohoba J; Dong BJ
Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
[TBL] [Abstract][Full Text] [Related]
7. Lack of a clinically meaningful pharmacokinetic effect of rifabutin on raltegravir: in vitro/in vivo correlation.
Brainard DM; Kassahun K; Wenning LA; Petry AS; Liu C; Lunceford J; Hariparsad N; Eisenhandler R; Norcross A; DeNoia EP; Stone JA; Wagner JA; Iwamoto M
J Clin Pharmacol; 2011 Jun; 51(6):943-50. PubMed ID: 20852006
[TBL] [Abstract][Full Text] [Related]
8. Raltegravir thorough QT/QTc study: a single supratherapeutic dose of raltegravir does not prolong the QTcF interval.
Iwamoto M; Kost JT; Mistry GC; Wenning LA; Breidinger SA; Marbury TC; Stone JA; Gottesdiener KM; Bloomfield DM; Wagner JA
J Clin Pharmacol; 2008 Jun; 48(6):726-33. PubMed ID: 18441333
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
Nunes T; Machado R; Rocha JF; Fernandes-Lopes C; Costa R; Torrão L; Loureiro AI; Falcão A; Vaz-da-Silva M; Wright L; Almeida L; Soares-da-Silva P
Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897
[TBL] [Abstract][Full Text] [Related]
10. The effect of rilpivirine on the pharmacokinetics of methadone in HIV-negative volunteers.
Crauwels HM; van Heeswijk RP; Vandevoorde A; Buelens A; Stevens M; Hoetelmans RM
J Clin Pharmacol; 2014 Feb; 54(2):133-40. PubMed ID: 24203510
[TBL] [Abstract][Full Text] [Related]
11. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.
Iwamoto M; Wenning LA; Petry AS; Laethem M; De Smet M; Kost JT; Merschman SA; Strohmaier KM; Ramael S; Lasseter KC; Stone JA; Gottesdiener KM; Wagner JA
Clin Pharmacol Ther; 2008 Feb; 83(2):293-9. PubMed ID: 17713476
[TBL] [Abstract][Full Text] [Related]
12. Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir.
Iwamoto M; Wenning LA; Petry AS; Laethem M; De Smet M; Kost JT; Breidinger SA; Mangin EC; Azrolan N; Greenberg HE; Haazen W; Stone JA; Gottesdiener KM; Wagner JA
Antimicrob Agents Chemother; 2008 Dec; 52(12):4338-43. PubMed ID: 18838589
[TBL] [Abstract][Full Text] [Related]
13. Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir.
de Kanter CT; Blonk MI; Colbers AP; Schouwenberg BJ; Burger DM
Clin Infect Dis; 2013 Jan; 56(2):300-6. PubMed ID: 23001704
[TBL] [Abstract][Full Text] [Related]
14. The effect of raltegravir on the glucuronidation of lamotrigine.
van Luin M; Colbers A; Verwey-van Wissen CP; van Ewijk-Beneken-Kolmer EW; van der Kolk M; Hoitsma A; da Silva HG; Burger DM
J Clin Pharmacol; 2009 Oct; 49(10):1220-7. PubMed ID: 19717722
[TBL] [Abstract][Full Text] [Related]
15. Effect of low-, moderate-, and high-fat meals on raltegravir pharmacokinetics.
Brainard DM; Friedman EJ; Jin B; Breidinger SA; Tillan MD; Wenning LA; Stone JA; Chodakewitz JA; Wagner JA; Iwamoto M
J Clin Pharmacol; 2011 Mar; 51(3):422-7. PubMed ID: 20457591
[No Abstract] [Full Text] [Related]
16. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.
Martínez E; Larrousse M; Llibre JM; Gutiérrez F; Saumoy M; Antela A; Knobel H; Murillas J; Berenguer J; Pich J; Pérez I; Gatell JM;
AIDS; 2010 Jul; 24(11):1697-707. PubMed ID: 20467288
[TBL] [Abstract][Full Text] [Related]
17. Raltegravir with optimized background therapy for resistant HIV-1 infection.
Steigbigel RT; Cooper DA; Kumar PN; Eron JE; Schechter M; Markowitz M; Loutfy MR; Lennox JL; Gatell JM; Rockstroh JK; Katlama C; Yeni P; Lazzarin A; Clotet B; Zhao J; Chen J; Ryan DM; Rhodes RR; Killar JA; Gilde LR; Strohmaier KM; Meibohm AR; Miller MD; Hazuda DJ; Nessly ML; DiNubile MJ; Isaacs RD; Nguyen BY; Teppler H;
N Engl J Med; 2008 Jul; 359(4):339-54. PubMed ID: 18650512
[TBL] [Abstract][Full Text] [Related]
18. Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies.
Burger DM
Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1151-60. PubMed ID: 20701552
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy.
Liu P; Foster G; Labadie R; Somoza E; Sharma A
Antimicrob Agents Chemother; 2007 Jan; 51(1):110-8. PubMed ID: 17074798
[TBL] [Abstract][Full Text] [Related]
20. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.
Vaz-da-Silva M; Almeida L; Falcão A; Soares E; Maia J; Nunes T; Soares-da-Silva P
Clin Ther; 2010 Jan; 32(1):179-92. PubMed ID: 20171423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]